Company
Every published round OneVentures Innovation Fund took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies OneVentures Innovation Fund has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Investors that coverage says has money in a fund OneVentures Innovation Fund runs. This is a stake in the fund, not in any company the fund has backed.
| Investor | Fund | Sources |
|---|---|---|
| Australian Government | OneVentures Innovation Fund | GBS Ventures (12 Dec 2013), GBS Ventures (31 Oct 2013), GBS Ventures (2 Dec 2011) |
Companies OneVentures Innovation Fund has backed that another company then bought. An exit for the holding, not a deal OneVentures Innovation Fund did.
Stories naming OneVentures Innovation Fund. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Hatchtech announced FDA sign-off on its DeOvo Phase 3 trials and two extra patents; its profile names GBS Venture Partners among the company's investors.
Melbourne drug developer Hatchtech raised A$12.6 million, with OneVentures Innovation Fund leading, to advance its head lice treatment toward Phase III trials; board changes brought in Richard Treagus and Hugh Alsop.
Australian pharmaceutical developer Hatchtech appoints Tim Waugh, a former Roche divisional vice president, as chief executive officer to lead development and commercialisation of its head lice treatment DeOvo and establish a United States presence.